ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adaptive Biotechnologies Corp (ADPT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive growth potential and strong analyst support, the recent insider selling, declining net income, and bearish technical indicators suggest caution. The stock may be better suited for monitoring rather than immediate investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 51.677, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 13.595, with resistance at 14.292 and support at 12.898. Overall, the technical indicators suggest a cautious approach.
Hedge funds are buying, with a 176.86% increase in buying activity over the last quarter.
Analysts have raised price targets recently, with BTIG, TD Cowen, and JPMorgan highlighting strong growth potential and a solid Q4 performance.
Revenue increased by 51.04% YoY in Q4 2025, and gross margin improved significantly to 73.98%.
Insiders are selling heavily, with a 380.60% increase in selling activity over the last month.
Key executives, including the COO and Chief People Officer, sold significant shares recently.
Net income dropped by 59.70% YoY, and EPS declined by 60.87% YoY in Q4
The stock price has been declining recently, with a -1.34% regular market change and bearish moving averages.
In Q4 2025, revenue grew by 51.04% YoY to $71.68 million, and gross margin improved to 73.98%, up 21.12% YoY. However, net income dropped to -$13.58 million (-59.70% YoY), and EPS fell to -0.09 (-60.87% YoY), indicating profitability challenges.
Analysts are bullish on ADPT, with multiple firms raising price targets recently. BTIG raised its target to $22, TD Cowen and JPMorgan to $21, citing strong Q4 results and growth drivers such as EMR integrations and new indications. The consensus is positive, with a Buy or Overweight rating maintained across the board.
